AUAna Helena Dias Pereira dos Santos Ulbrich

Ana Helena Dias Pereira dos Santos Ulbrich

*This is an algorithmically generated author record based on publicly available information.

Ana Helena Dias Pereira dos Santos Ulbrich has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Pharmacist-Led Assessment of Drug-Induced Liver Injury in Hospitalized Patients

    by Gabriela Xavier Ortiz, Karin Hepp Schwambach, Ana Helena Dias Pereira dos Santos Ulbrich, Henrique Dias Pereira dos Santos, Matheus William Becker, Carine Raquel Blatt

    Background: Drug-induced liver injury (DILI) is an important but underdiagnosed adverse drug reaction in hospitalized patients. The complexity of diagnosis, under-reporting, and a lack of standardized assessment tools contribute to underestimation of its prevalence. Objectives: To estimate the prevalence of DILI in a tertiary care hospital and to discuss the role of clinical pharmacists in using the Roussel Uclaf Causality Assessment Method (RUCAM) to detect, assess, and manage DILI. Methods: This cross-sectional study included patients who were admitted between January and June 2022 to a tertiary care hospital in Porto Alegre, Brazil. All hospitalized patients with alanine aminotransferase (ALT) levels at least 3 times the upper limit of normal at any point during the hospital stay were screened. Suspected cases of DILI were evaluated by trained pharmacists using the RUCAM. Data were collected retrospectively from electronic medical records and analyzed using descriptive and inferential statistics. Results: Of 56 014 patients admitted to the hospital during the study period, 1274 had elevated ALT, of whom 38 were classified by the RUCAM as having DILI. Among these, 33 (87%) experienced development of DILI during the hospital stay. Most of the patients (n = 29, 76%) were in general hospital wards, and this factor showed a significant association with occurrence of DILI. Anti-infectives were the most commonly implicated drugs (69%), specifically the combination of rifampicin, isoniazid, pyrazinamide, and ethambutol and various β-lactams. Simvastatin was also commonly implicated. None of the DILI cases were reported to the institutional pharmacovigilance system. Conclusions: DILI remains under-recognized and under-reported in hospital settings. This study reinforces the potential role of clinical pharmacists in active surveillance using RUCAM and highlights the need for institutional strategies prioritizing the monitoring of liver function in high-risk patients, particularly on general wards. Keywords: drug-induced liver injury, hospital pharmacy, patient safety, pharmacovigilance RÉSUMÉ Contexte : La lésion hépatique d’origine médicamenteuse (LHOM) est une réaction indésirable importante, mais souvent sous-diagnostiquée chez les patients hospitalisés. La complexité du diagnostic, la sous déclaration des cas et le manque d’outils d’évaluation standardisés contribuent à la sous-estimation de sa prévalence. Objectifs : Estimer la prévalence de la LHOM dans un hôpital de soins tertiaires et discuter du rôle des pharmaciens cliniciens dans la détection, l’évaluation et la prise en charge de la LHOM à l’aide de la méthode d’évaluation de la causalité Roussel Uclaf (échelle RUCAM). Méthodologie : Cette étude transversale comprenait des patients admis de janvier à juin 2022 dans un établissement de soins tertiaires à Porto Alegre, au Brésil. Tous les patients hospitalisés dont le taux d’alanine aminotransférase (ALT) était supérieur ou égal à trois fois la limite supérieure de la normale à un moment quelconque de l’hospitalisation ont été sélectionnés. Les cas suspects de LHOM ont été évalués à l’aide de l’échelle RUCAM par des pharmaciens formés. Les données ont été recueillies rétrospectivement à partir des dossiers médicaux électroniques et analysées à l’aide de statistiques descriptives et inférentielles. Résultats : Sur les 56 014 patients admis à l’hôpital pendant la période de l’étude, les taux d’ALT de 1274 patients étaient élevés, dont 38 qui ont été classés comme ayant une LHOM selon l’échelle RUCAM. Parmi ceux-ci, 33 patients (87 %) ont développé une LHOM au cours de leur séjour. La majorité des patients (n = 29, 76 %) se trouvaient dans des unités d’hospitalisation générale. Ce facteur a démontré une association significative avec la survenue de la LHOM. Les médicaments anti-infectieux étaient les plus fréquemment associés à cette dernière (69 %), en particulier la combinaison rifampicine, isoniazide, pyrazinamide et éthambutol, ainsi que divers β-lactamines. La simvastatine y était, elle aussi, fréquemment associée. Aucun des cas de LHOM n’a été signalé au système institutionnel de pharmacovigilance. Conclusions : La LHOM demeure sous-reconnue et sous-déclarée en milieu hospitalier. Cette étude renforce le rôle potentiel des pharmaciens cliniciens dans la surveillance active à l’aide de l’échelle RUCAM et souligne la nécessité de stratégies institutionnelles visant à prioriser le suivi de la fonction hépatique chez les patients à haut risque, en particulier dans les unités d’hospitalisation générales. Mots-clés : lésion hépatique d’origine médicamenteuse, pharmacie d’hôpital, sécurité du patient, pharmacovigilance


  • Open Access

    IMPACTO DA TRANSIÇÃO DE CUIDADO NOS DESFECHOS CLÍNICOS: COORTE HISTÓRICA

    by Jociele Gheno, Ana Helena Dias Pereira dos Santos Ulbrich, Ana Paula Fabbris Andreatta, Patrícia Fish, Roberta Cristina Petry, Thaise da Silva Nunes, Alisia Helena Weis

    RESUMO Objetivo: verificar o impacto da transição de cuidado nas reinternações e nos óbitos em 30 dias após a alta dos pacientes adultos e idosos. Método: estudo de coorte histórica realizado em um hospital de nível terciário do sul do Brasil. Foram incluídos todos os pacientes para os quais foi realizado contato com os serviços da rede de atenção à saúde para transição de cuidado no momento da alta, no ano de 2019. Os dados foram analisados por meio do software Statistical Package for the Social Sciences (SPSS), versão 20.0. Resultado: foram realizados 705 contatos com os serviços da rede de atenção para as transições do cuidado de pacientes no momento da alta. Ocorreram 3% de perdas de seguimento, sendo assim, 684 pacientes foram considerados para a avaliação da reinternação e óbito em 30 dias após a alta. Dos acompanhamentos pactuados com os serviços da rede no momento da alta, 73,5% deles foram realizados. Quando comparados ao grupo de pacientes que tiveram acompanhamento realizado com o grupo que não recebeu acompanhamento após a alta, o primeiro grupo teve menores taxas de reinternação e óbito em 30 dias após a alta (para reinternação: 19,7% vs. 28,7%; p=0,001 e para óbito: 5,8 % vs. 13,8 %; p=0,012). Conclusão: os resultados do estudo reforçam o impacto que a transição de cuidado tem nas reinternações e nos óbitos após a alta, reafirmam a importância da articulação e da comunicação entre os serviços de saúde na qualificação e segurança das transições.


  • Open Access

    IMPACT OF TRANSITION OF CARE ON CLINICAL OUTCOMES: HISTORICAL COHORT

    by Jociele Gheno, Ana Helena Dias Pereira dos Santos Ulbrich, Ana Paula Fabbris Andreatta, Patrícia Fish, Roberta Cristina Petry, Thaise da Silva Nunes, Alisia Helena Weis

    Objective to verify the impact of transition of care on readmissions and deaths within 30 days after discharge of adult and elderly patients. Method this is a historical cohort study conducted in a tertiary hospital in southern Brazil. All patients for whom contact was made with the healthcare network services for transition of care at discharge in 2019 were included. Data were analyzed using the Statistical Package for the Social Sciences version 20.0. Result a total of 705 contacts were made with care network services for patient transitions of care at discharge. There were 3% losses to follow-up. Therefore, 684 patients were considered for readmission assessment and death within 30 days after discharge. Of the follow-ups agreed with the network services at discharge, 73.5% of them were carried out. When compared to the group of patients who had follow-up performed with the group that did not receive follow-up after discharge, the first group had lower rates of readmission and death within 30 days after discharge (for readmission: 19.7% vs. 28.7%; p=0.001 and for death: 5.8% vs. 13.8%; p=0.012). Conclusion the results of this study reinforce the impact that transition of care has on readmissions and deaths after discharge, reaffirming the importance of coordination and communication between healthcare services in transition qualification and safety.


  • Open Access

    Potenciais interações medicamentosas em adultos e idosos no ambiente hospitalar

    by Ana Helena Ulbrich, Juliana Damasio Oliveira, Júlia Colleoni Couto, Giovana Xavier Ortiz, Catherine Stragliotto Isoppo

    Objetivo: determinar a prevalência de interações medicamentosas potencialmente graves em pacientes adultos e idosos no ambiente hospitalar público, misto e privado. Métodos: estudo transversal com prescrições de 27.088 pacientes maiores de 18 anos divididos entre os grupos “Adultos” e “Idosos”, de seis hospitais públicos e cinco hospitais mistos e privados em três regiões do Brasil em fevereiro de 2023. Os dados foram coletados da plataforma NoHarm, ferramenta utilizada para organizar o processo de trabalho do farmacêutico clínico. Foram analisadas potenciais interações medicamentosas classificadas como graves ou contraindicadas. Resultados: um total de 128.143 prescrições foram incluídas no estudo, sendo 47,8% do grupo dos adultos e 52,2% do grupo dos idosos. A presença de, pelo menos, uma interação potencial no total de prescrições foi igual a 22,3%, sendo mais frequente na população idosa (24,5% vs. 19,9%, P < 0.001), do sexo masculine (24,7% vs. 20,2%, P < 0,001), internada em hospital público (27,8% vs. 16,1%, P < 0,001) e com maior quantidade de itens prescritos (18 vs. 3 itens, P < 0,001). O total de interações medicamentosas encontradas foi de 71.047, sendo mais prevalentes os medicamentos psicoativos e aqueles que atuam no sistema gastrointestinal, tanto no grupo dos adultos (32,9%), quanto no grupo dos idosos (22,4%). Conclusão: este estudo identificou alta prevalência (22,3%) de interações medicamentosas em pacientes hospitalizados, sobretudo entre os pacientes idosos e em hospitais públicos. As classes de medicamentos envolvidos nas interações variaram entre os grupos de adultos e idosos.